Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

BMS Opdivo To Make Splash in Blood Cancer

Executive Summary

New data show that Bristol-Myers Squibb Co.'s Opdivo (nivolumab) has promise in treating Hodgkin's lymphoma reinforcing the notion that checkpoint inhibitors have potential in a broad range of cancers.

Advertisement

Related Content

Seattle Genetics/BMS Blood Cancer Tie-Up May Expand After Good Combo Data
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
Merck's Keytruda Gets Lung Cancer Nod In Europe

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register